Cancer Network Metastatic Colorectal Cancer: Patient Presentation, Diagnosis, and Treatment Comprehensive insights into the stratification, diagnosis, and treatment of patients with metastatic colorectal cancer. .10 hours ago
Cancer Network Metastatic Colorectal Cancer: Patient Presentation, Diagnosis, and Treatment Comprehensive insights into the stratification, diagnosis, and treatment of patients with metastatic colorectal cancer. .10 hours ago
FDA approves Fluzakura for treatment of refractory metastatic colorectal cancer
November 9, 2023 2 minute read Add topics to email alerts Receive an email when a new article is posted Enter your email address to receive emails when new articles are posted. . ” data-action=”subscribe”> Subscribe Your request could not be processed. Please try again later. If you continue to experience […]
FDA approves Fluzakura for previously treated metastatic colorectal cancer
The Food and Drug Administration (FDA) has approved Fluzakura (fruquintinib) for the treatment of some adults with metastatic colorectal cancer (mCRC), biopharmaceutical company Takeda Pharmaceutical announced in a news release. Patients are eligible for treatment with Fluzacra, an oral targeted therapy, after treatment with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy and anti-VEGF therapy. Patients with wild-type RAS […]
FDA approves fruquintinib for metastatic colorectal cancer
Approved by the US Food and Drug Administration fruquintinib (Furuzakura, Takeda) Treatment for certain metastatic adults colorectal cancer People who have experienced disease progression during or after previous treatment. More specifically, this approval also extends to adult patients with metastatic colorectal cancer who have previously received fluoropyrimidine, oxaliplatin, or irinotecan-based chemotherapy, anti-VEGF therapy, and in […]
FDA approves fruquintinib for metastatic colorectal cancer
The FDA has approved fruquintinib (Fluzacra) for the treatment of adult patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy, or anti-VEGF therapy. R.A.S. Wild-type, medically relevant anti-EGFR therapy.1 This approval was based on results from the multiregional phase 3 FRESCO-2 trial (NCT04322539) and the Chinese phase 3 FRESCO trial […]
Sotorasib and panitumumab named new standard of care for metastatic colorectal cancer
The combination of sotorasib and panitumumab outperformed researchers’ treatment of choice in a phase 3 trial in chemotherapy-resistant patients. classG12C– Mutant metastatic colorectal cancer (CRC). Researchers tested the combination with two different doses of sotorasib and found that both doses improved progression-free survival (PFS). However, outcomes were better with higher doses of sotorasib. “The combination […]
A combination that beats standard treatments for metastatic colorectal cancer
October 23, 2023 2 minute read Add topics to email alerts Receive an email when a new article is posted Enter your email address to receive emails when new articles are posted. . ” data-action=”subscribe”> Subscribe Your request could not be processed. Please try again later. If you continue to experience […]
Targeted combination therapy triumphs in KRAS-positive metastatic colorectal cancer
MADRID — The combination of a KRAS G12C inhibitor and an EGFR inhibitor significantly improved progression-free survival (PFS) compared to standard of care in patients with chemotherapy-resistant metastatic colorectal cancer (mCRC). was shown in the randomized phase III CodeBreaK 300 trial. With a median follow-up of 7.8 months, median PFS was 5.6 months for patients […]
More aggressive treatment has no impact on quality of life for patients with metastatic colorectal cancer, according to new study in JNCCN
Researchers have found that in patients with multivisceral metastatic colorectal cancer, removing as much tumor as possible using various methods does not reduce quality of life, although it increases adverse events. Survival benefits are still unknown. Plymouth Meeting, Pennsylvania, October 12, 2023 /PRNewswire/ — New research in October 2023 Problem of JNCCN—Journal of the National […]
More aggressive treatment for metastatic colorectal cancer does not affect quality of life
New research in October 2023 issue JNCCN—Journal of the National Comprehensive Cancer Network In addition to standard systemic therapy, intensive local treatment to remove as much tumor as possible (known as “debulking”) has a significant impact on the overall quality of life of patients with metastatic colorectal cancer. I discovered that it does not give […]